NOGEA

NOGEA quantifies the perturbation abilities of disease-associated genes to identify master genes and prioritize gene-disease relationships using directed disease-specific gene networks.

Key Features:

• Network-oriented gene entropy: Applies a gene-entropy metric to quantify the perturbation ability of individual genes within directed disease-specific gene networks.
• Master gene inference: Infers master genes that significantly contribute to specific diseases based on their calculated entropy and perturbation effects.
• DAG prioritization: Quantitatively prioritizes disease-associated genes (DAGs) derived from high-throughput datasets by their network perturbation potential.
• Directed network modeling: Utilizes directed disease-specific gene networks to model directionality of perturbation propagation among genes.
• Disease initiation and progression prediction: Predicts disease-specific initiation events and progression risks from gene entropy and perturbation metrics.
• Interactome topology analysis: Analyzes topological localization of approved therapeutic targets relative to master genes within the interactome network to support drug-disease association predictions.
• Drug repositioning evidence: Identified 11 existing drugs with potential efficacy against pancreatic cancer, with validation reported by in vitro experiments.

Scientific Applications:

• Master gene identification: Identification of master genes that control disease initiation and co-occurrence to inform disease mechanism studies.
• Disease comorbidity analysis: Analysis of how master genes contribute to disease co-occurrence and comorbidity patterns.
• Drug repositioning and target prioritization: Prediction of new drug-disease associations and prioritization of therapeutic targets, including application to pancreatic cancer drug repurposing.

Methodology:

Computes network-oriented gene entropy by quantitatively calculating perturbation abilities of DAGs on directed disease-specific gene networks and analyzes topological localization within the interactome to associate therapeutic targets and predict drug-disease links.